Melanoma with unknown primary: Report and analysis of 24 patients

Rita Clerico, Ugo Bottoni, Giovanni Paolino, Marina Ambrifi, Paola Corsetti, Valeria Devirgiliis, Stefano Calvieri

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In the literature, there are some papers reporting on patients with metastatic melanoma from an unknown primary lesion (MUP). The pathogenesis of this phenomenon and the prognosis of these patients are still debatable. Therefore, we reviewed our casistics on MUP patients. We identified 24 MUP patients out of all patients registered into a melanoma database from June 1996 to June 2011. The incidence was 1.4 %. We compared the survival rate of all patients with MUP stage III-IV with all patients with metastatic melanoma known primary (MMKP) stage III-IV observing a clear survival improvement for MUP patients in front of MMKP patients (p <0.01). In a second instance, we compared stage III MUP patients with only lymph nodal involvement with stage III MMKP patients with only lymph nodal involvement, and again we found statistically significant better survival for MUP patients (p <0.05). In this retrospective study, the number of lymph nodes involved (p = 0.8), the sex (p = 0.9), and S100 value (p = 0.2) were not statistically relevant for prognosis. The better prognosis for these patients is very similar to better survival rate for metastatic melanoma patients and vitiligo. This correlation may be in accord with the hypothesis of a regression of primary lesion by immunological system of the host and also the median age of patients at the time of diagnosis, commonly older than melanoma patients, may correspond to a long period of immunological interferences between the host and the melanoma disease.

Original languageEnglish
Pages (from-to)2978-2984
Number of pages7
JournalMedical Oncology
Volume29
Issue number4
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Melanoma
Lymph
Survival Rate
Vitiligo
Survival
Retrospective Studies
Lymph Nodes
Databases

Keywords

  • Immune system
  • Melanocytes
  • Melanoma
  • Occult primary
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Clerico, R., Bottoni, U., Paolino, G., Ambrifi, M., Corsetti, P., Devirgiliis, V., & Calvieri, S. (2012). Melanoma with unknown primary: Report and analysis of 24 patients. Medical Oncology, 29(4), 2978-2984. https://doi.org/10.1007/s12032-012-0217-9

Melanoma with unknown primary : Report and analysis of 24 patients. / Clerico, Rita; Bottoni, Ugo; Paolino, Giovanni; Ambrifi, Marina; Corsetti, Paola; Devirgiliis, Valeria; Calvieri, Stefano.

In: Medical Oncology, Vol. 29, No. 4, 12.2012, p. 2978-2984.

Research output: Contribution to journalArticle

Clerico, R, Bottoni, U, Paolino, G, Ambrifi, M, Corsetti, P, Devirgiliis, V & Calvieri, S 2012, 'Melanoma with unknown primary: Report and analysis of 24 patients', Medical Oncology, vol. 29, no. 4, pp. 2978-2984. https://doi.org/10.1007/s12032-012-0217-9
Clerico R, Bottoni U, Paolino G, Ambrifi M, Corsetti P, Devirgiliis V et al. Melanoma with unknown primary: Report and analysis of 24 patients. Medical Oncology. 2012 Dec;29(4):2978-2984. https://doi.org/10.1007/s12032-012-0217-9
Clerico, Rita ; Bottoni, Ugo ; Paolino, Giovanni ; Ambrifi, Marina ; Corsetti, Paola ; Devirgiliis, Valeria ; Calvieri, Stefano. / Melanoma with unknown primary : Report and analysis of 24 patients. In: Medical Oncology. 2012 ; Vol. 29, No. 4. pp. 2978-2984.
@article{da23c1a8b6bf43bb968e63798389048b,
title = "Melanoma with unknown primary: Report and analysis of 24 patients",
abstract = "In the literature, there are some papers reporting on patients with metastatic melanoma from an unknown primary lesion (MUP). The pathogenesis of this phenomenon and the prognosis of these patients are still debatable. Therefore, we reviewed our casistics on MUP patients. We identified 24 MUP patients out of all patients registered into a melanoma database from June 1996 to June 2011. The incidence was 1.4 {\%}. We compared the survival rate of all patients with MUP stage III-IV with all patients with metastatic melanoma known primary (MMKP) stage III-IV observing a clear survival improvement for MUP patients in front of MMKP patients (p <0.01). In a second instance, we compared stage III MUP patients with only lymph nodal involvement with stage III MMKP patients with only lymph nodal involvement, and again we found statistically significant better survival for MUP patients (p <0.05). In this retrospective study, the number of lymph nodes involved (p = 0.8), the sex (p = 0.9), and S100 value (p = 0.2) were not statistically relevant for prognosis. The better prognosis for these patients is very similar to better survival rate for metastatic melanoma patients and vitiligo. This correlation may be in accord with the hypothesis of a regression of primary lesion by immunological system of the host and also the median age of patients at the time of diagnosis, commonly older than melanoma patients, may correspond to a long period of immunological interferences between the host and the melanoma disease.",
keywords = "Immune system, Melanocytes, Melanoma, Occult primary, Survival",
author = "Rita Clerico and Ugo Bottoni and Giovanni Paolino and Marina Ambrifi and Paola Corsetti and Valeria Devirgiliis and Stefano Calvieri",
year = "2012",
month = "12",
doi = "10.1007/s12032-012-0217-9",
language = "English",
volume = "29",
pages = "2978--2984",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "4",

}

TY - JOUR

T1 - Melanoma with unknown primary

T2 - Report and analysis of 24 patients

AU - Clerico, Rita

AU - Bottoni, Ugo

AU - Paolino, Giovanni

AU - Ambrifi, Marina

AU - Corsetti, Paola

AU - Devirgiliis, Valeria

AU - Calvieri, Stefano

PY - 2012/12

Y1 - 2012/12

N2 - In the literature, there are some papers reporting on patients with metastatic melanoma from an unknown primary lesion (MUP). The pathogenesis of this phenomenon and the prognosis of these patients are still debatable. Therefore, we reviewed our casistics on MUP patients. We identified 24 MUP patients out of all patients registered into a melanoma database from June 1996 to June 2011. The incidence was 1.4 %. We compared the survival rate of all patients with MUP stage III-IV with all patients with metastatic melanoma known primary (MMKP) stage III-IV observing a clear survival improvement for MUP patients in front of MMKP patients (p <0.01). In a second instance, we compared stage III MUP patients with only lymph nodal involvement with stage III MMKP patients with only lymph nodal involvement, and again we found statistically significant better survival for MUP patients (p <0.05). In this retrospective study, the number of lymph nodes involved (p = 0.8), the sex (p = 0.9), and S100 value (p = 0.2) were not statistically relevant for prognosis. The better prognosis for these patients is very similar to better survival rate for metastatic melanoma patients and vitiligo. This correlation may be in accord with the hypothesis of a regression of primary lesion by immunological system of the host and also the median age of patients at the time of diagnosis, commonly older than melanoma patients, may correspond to a long period of immunological interferences between the host and the melanoma disease.

AB - In the literature, there are some papers reporting on patients with metastatic melanoma from an unknown primary lesion (MUP). The pathogenesis of this phenomenon and the prognosis of these patients are still debatable. Therefore, we reviewed our casistics on MUP patients. We identified 24 MUP patients out of all patients registered into a melanoma database from June 1996 to June 2011. The incidence was 1.4 %. We compared the survival rate of all patients with MUP stage III-IV with all patients with metastatic melanoma known primary (MMKP) stage III-IV observing a clear survival improvement for MUP patients in front of MMKP patients (p <0.01). In a second instance, we compared stage III MUP patients with only lymph nodal involvement with stage III MMKP patients with only lymph nodal involvement, and again we found statistically significant better survival for MUP patients (p <0.05). In this retrospective study, the number of lymph nodes involved (p = 0.8), the sex (p = 0.9), and S100 value (p = 0.2) were not statistically relevant for prognosis. The better prognosis for these patients is very similar to better survival rate for metastatic melanoma patients and vitiligo. This correlation may be in accord with the hypothesis of a regression of primary lesion by immunological system of the host and also the median age of patients at the time of diagnosis, commonly older than melanoma patients, may correspond to a long period of immunological interferences between the host and the melanoma disease.

KW - Immune system

KW - Melanocytes

KW - Melanoma

KW - Occult primary

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84868004556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868004556&partnerID=8YFLogxK

U2 - 10.1007/s12032-012-0217-9

DO - 10.1007/s12032-012-0217-9

M3 - Article

C2 - 22460835

AN - SCOPUS:84868004556

VL - 29

SP - 2978

EP - 2984

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

ER -